OncLive TV

Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.

Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.

John Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.

Mariana X. Byndloss, DVM, PhD, discusses the relationship between the gut microbiome and the risk of developing cancers such as colorectal cancer.

R. Wendel Naumann, MD, FACOG, FACS, discusses how the evolution of immunotherapy has changed the treatment landscape for patients with recurrent or metastatic cervical cancer.

Thomas M. Habermann, MD, discusses the data that led to the decision to withdraw the indication for ibrutinib for the treatment of patients with mantle cell lymphoma.

Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.

Susan Bal, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Michael K. Gibson MD, PhD, discusses advancements in the identification of key biomarkers for patients with gastric or gastroesophageal junction adenocarcinoma, and the subsequent development of biomarker-driven therapeutics in this disease space.

Matthew Galsky, MD, discusses the importance of developing specific disease classifications within non–clear cell renal cell carcinomas.

Joshua Reuss, MD, discusses the background of LP-300 and the rationale for evaluating the agent in the phase 2 HARMONIC trial in a never-smoker population of patients with advanced lung adenocarcinoma.

Thomas M. Habermann, MD, discusses the withdrawal of United States indications for ibrutinib in patients with mantle cell lymphoma who have previously received at least 1 therapy and in those with marginal zone lymphoma who require systemic treatment and have received at least 1 prior anti–CD20-based therapy.

Christopher W. Ryan, MD, discusses the role of adjuvant therapy for patients with renal cell carcinoma.

Laura Goff, MD, discusses the key takeaways from results of the phase 3 SWOG 1815 trial in newly diagnosed patients with advanced biliary tract cancers.

Jeffery Zonder, MD, discusses the management of toxicities associated with bispecific antibodies in patients with multiple myeloma.

Maya Khalil, MD, discusses the use of first-line durvalumab plus tremelimumab in patients with non–small cell lung cancer enrolled in the phase 3 POSEIDON trial, and sheds light on histologies and mutations that are associated with increased benefit with this regimen.

Michael K. Gibson MD, PhD, discusses current and emerging biomarkers in the treatment of patients with gastric or gastroesophageal junction adenocarcinoma.

John Mascarenhas, MD, discusses the background of the phase 3 MANIFEST-2 trial investigating the combination of pelabresib and ruxolitinib vs ruxolitinib plus placebo in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.

Che-Kai Tsao, MD, discusses first-line treatment approaches for patients with clear cell renal cell carcinoma.

Karen S. Anderson, MD, PhD, discusses novel and emerging therapies, as well as potential future targets, for the treatment of patients with hormone receptor–positive breast cancer.

Devika Das, MD, MSHQS, discusses the activity and tolerability of lurbinectedin and topotecan as second-line regimens in extensive-stage small cell lung cancer.

Luis G. Paz-Ares, MD, PhD, discusses the importance of next-generation sequencing and highlights current challenges with NGS for patients with non–small cell lung cancer.

Neal Shore, MD, FACS, discusses the rationale for the phase 3 EMBARK trial investigating enzalutamide plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Meera Mohan, MD, MS, FACP, discusses adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.

Tania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.

Neelam Desai, MD, discusses the toxicity profile of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

J. Randolph Hecht, MD, discusses the investigation of A2B530 in germline HLA-A*02 heterozygous solid tumors.

Karen S. Anderson, MD, PhD, discusses the evolution of antibody-drug conjugates in the treatment of different subgroups of patients with metastatic breast cancer.

Efstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.

Chandler Park, MD, MSc, FACP, discusses the navigation and selection of later-line treatments for patients with metastatic urothelial carcinoma.